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Abstract
Introduction: Obtaining an adequate number of high-quality oocytes is a major challenge in controlled ovarian
hyperstimulation (COH). To date, a range of hormonal and clinical parameters have been used to optimize COH but none
have significant predictive value. This variability could be due to the genetic predispositions of single-nucleotide
polymorphisms (SNPs). Here, we assessed the individual and combined impacts of thirteen SNPs that reportedly influence
the outcome of in vitro fertilisation (IVF) on the ovarian response to rFSH stimulation for patients undergoing
intracytoplasmic sperm injection program (ICSI).
Results: Univariate analysis revealed that only FSHR, ESR2 and p53 SNPs influenced the number of mature oocytes. The
association was statistically significant for FSHR (p=0.0047) and ESR2 (0.0017) in the overall study population and for FSHR
(p=0.0009) and p53 (p=0.0048) in subgroup that was more homogeneous in terms of clinical variables. After Bonferroni
correction and a multivariate analysis, only the differences for FSHR and ESR2 polymorphisms were still statistically
significant. In a multilocus analysis, only the FSHR and AMH SNP combination significantly influenced oocyte numbers in
both population (p,0.01).
Discussion: We confirmed the impact of FSHR and ESR2 polymorphisms on the IVF outcome. Furthermore, we showed for
the first time that a p53 polymorphism (which is already known to impact embryo implantation) could influence the ovarian
response. However, given that this result lost its statistical significance after multivariate analysis, more data are needed to
draw firm conclusions. Only the FSHR and AMH polymorphism combination appears to influence mature oocyte numbers
but this finding also needs to be confirmed.
Materials and Methods: A 13 gene polymorphisms: FSHR(Asn680Ser), p53(Arg72Pro), AMH(Ile49Ser), ESR2(+1730G.A),
ESR1(2397T.C), BMP15(29C.G), MTHFR1(677C.T), MTHFR2(1298A.C), HLA-G(2725C.G), VEGF(+405G.C),
TNFa(2308A.G), AMHR(2482 A.G), PAI-1 (4 G/5 G), multiplex PCR assay was designed to genotype women undergoing
ICSI program. We analyzed the overall study population (n=427) and a subgroup with homogeneous characteristics
(n=112).
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Introduction
In vitro fertilization (IVF) is a complex, multistep process.
Oocytes-containing follicles are collected after controlled ovarian
hyperstimulation (COH) with follicle stimulating hormone (FSH).
Some of the subsequently fertilized oocytes will be transferred to
the uterus for implantation, whereas others may be cryopreserved
for future implantation attempts (or destroyed if they are unlikely
to survive cryopreservation). All these steps are critical for
successful IVF.
The aim of COH is to safely obtain a high number of mature
oocytes so that the most viable embryo can be selected for transfer.
Both quantitative and qualitative factors in oocyte production
have a high influence on the IVF outcome. The goal is to transfer
a single embryo and thus reduce the risk of multiple pregnancies -
the main complication of IVF [1].
The significant inter-individual variability to COH with FSH is
one of the most challenging issues in IVF treatment. Although low
responses are troublesome, high responses can trigger a serious
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38700medical condition - ovarian hyperstimulation syndrome (OHSS).
Hence, the ability to predict an individual’s responses to COH
would constitute a major advance in patient care. Although many
hormonal and clinical parameters (such as baseline FSH [2],
oestradiol [3], inhibin B [4] and anti-Mullerian hormone (AMH)
levels [5], patient age [6] and the antral follicle count [7]) have
been used to optimize COH, none of these markers have
significant predictive value when considered alone [8,9], However,
predictive performance levels can be improved by considering
combinations of these parameters [10].
Despite these advances in patient management, there is still a
need to individualise and optimise stimulation protocols, reduce
the likelihood of an extreme response and thus increase the
probability of a live birth. A complementary strategy involves
studying the pharmacogenetics of the COH response. Candidate
genes should have a specific effect on the reproductive system and
present single-nucleotide polymorphisms (SNPs) that affect gene
expression or function.
Gene association studies have identified a number of SNPs
(affecting gonadotrophin, steroid and TGFb pathways, etc.)
involved in the ovarian response. Most of them affect mRNA
levels or the protein sequence and thus lead to quantitative or
functional protein variations that may account for the observed
inter-individual variability in the COH. The first SNP to be
studied was the FSH receptor polymorphism Asn
680Ser, which
affects baseline FSH level and increases gonadotrophin require-
ments during COH [11,12]. The ESR1 (2397 T.C) polymor-
phism was positively correlated with low oocyte retrieval after
COH [13]. AMH (Ile
49Ser) and AMHR polymorphisms
(2482 A.G) have been associated with variations in oestradiol
levels and may modulate FSH sensitivity [14]. More recently, it
has been suggested that the COH outcome depends on
combinations of genetic and environmental factors [15]. In
support of this hypothesis, an oligo-SNP model (including FSHR:
Asn
680Ser, ESR1: 2397 T.C, and ESR2:,+1730 A.G poly-
morphism) was reportedly associated with a low response to FSH
during COH [13]. However, due to the small sample sizes and the
heterogeneity of the studied populations, the impact of these
polymorphisms requires further investigations.
Here, we sought to evaluate the impact of thirteen polymor-
phisms (all reportedly associated with variations in IVF results) in a
population of women undergoing intracytoplasmic sperm injection
(ICSI) program in our center. A multiplex PCR assay was
developed and statistical analysis was performed to evaluate the
SNPs individual and combined impacts on the COH outcome. We
studied the overall study population of patients undergoing ICSI
program and selected a subgroup that was homogeneous in terms
of patient characteristics.
Results
In the overall study population, we observed a significant
difference in the distribution of the oocyte number with age
(p,0.0001) and FSH level (p=0.0044). However, in the
homogeneous subgroup, only a slight difference in the distribution
of the oocyte number according to age (p=0.0289) was noted.
The allele frequencies in the homogeneous subgroup and in the
overall study population are listed in Table 1. The observed
Table 1. Allele frequencies of the studied SNPs in our population and in the NCBI database.
Candidate SNP Allele frequencies
Allele overall study population Homogeneous subgroup NCBI
AMH A/C 654 (76%)/206 (24%) 159 (71%)/65 (29%) 82%
18%
AMHR A
G
700 (82%)
156 (18%)
176 (79%)
48 (21%)
83%
17%
BMP15 C
G
193 (23%)
663 (77%)
65 (29%)
159 (71%)
23%
77%
ESR1 A
G
428 (52%)
398 (48%)
112 (50%)
112 (50%)
58%
42%
ESR2 G
A
520 (61%)
336 (39%)
136 (61%)
88 (39%)
62%
38%
FSHR A
G
475 (56%)
379 (44%)
136 (61%)
88 (39%)
60%
40%
HLA-G C
G
765 (90%)
89 (10%)
197 (88%)
27 (12%)
84%
16%
MTHFR1 T
C
216 (28%)
563 (72%)
81 (36%)
141 (63%)
31%
69%
MTHFR2 A
C
623 (73%)
227 (27%)
160 (73%)
60 (27%)
70%
30%
p53 C
G
272 (32%)
582 (68%)
70 (31%)
154 (69%)
26%
74%
PAI 4 G
4 G/5 G
445 (52%)
409 (48%)
119 (53%)
105 (47%)
50%
50%
TNF A
G
112 (14%)
676 (86%)
28 (12%)
206 (88%)
17%
83%
VEGF G
C
616 (78%)
176 (22%)
156 (75%)
52 (25%)
80%
20%
doi:10.1371/journal.pone.0038700.t001
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(http://www.ncbi.nlm.nih.gov/snp).
After a univariate analysis, only three of the thirteen SNPs
(FSHR (p.Asn
680Ser, +2039 A.G); p53 (p.Arg
72Pro, +215 C.G),
and oestradiol receptor 2 (+1730 G.A) polymorphisms) appeared
to be significantly associated with baseline characteristics and/or
the number of mature oocytes. These polymorphisms were in
Hardy-Weinberg equilibrium, with a 1% error interval.
The other polymorphisms (AMH, AMHR, BMP15, VEGF,
MTHFR1, MTHFR2, ESR1, TNFa, HLA-G and PAI) did not
appear to influence the number of mature oocytes collected
(Table 2).
After applying Holm’s correction and a multivariate analysis
(Table 3), the influence of p53 (p.Arg
72Pro) was no longer
statistically significant.
In a multilocus analysis of ESR2, p53, FSHR680 and AMH
polymorphisms, only the FSHR Asn
680Ser/AMH Ile
49Ser com-
bination was found to be associated with the number of mature
oocytes after COH.
The FSH Receptor Polymorphism (FSHR p.Asn
680Ser,
+2039 A.G) (Table 4)
In the overall study population, women with the Ser
680 variant
had significantly higher day-3 FSH and LH levels than women
who were homozygous for the Asn
680 variant (7.663.7 IU/l vs.
6.663.1 UI/l (p=0.0126) for FSH and 4.862.3 IU/l vs.
4.262.0 IU/l (p=0.0207) for LH, respectively). There was no
such association with day-3 FSH or LH levels in the homogeneous
subgroup (women under the age of 38 years old and with FSH
levels ,10 IU/l). The amount of FSH units administered and the
oestradiol level on the day of HCG administration were similar for
all genotypes in both the overall study population and the
homogeneous subgroup.
Surprisingly, women who were homozygous for the Ser
680
variant had a greater number of mature oocytes than women who
were homozygous for the Asn
680 variant, with averages of 8.164.3
vs. 7.163.9 oocytes (p=0.0047) in the overall study population
and 9.864.6 vs. 7.264.0 oocytes (p =0.0009) in the homogeneous
subgroup, respectively.
After applying Holm’s correction and a multivariate analysis,
the FSHR Asn
680Ser polymorphism was no longer statistically
significant in the overall study population. However, it was still
significantly correlated (p=0.0225) with the oocyte number in the
homogeneous subgroup.
Moreover, in the overall study population, we observed that
women who were homozygous for the Ser
680 variant were less
likely to have had a low response than women who were
homozygous for Asn
680 (18% vs. 27%, respectively). Likewise,
women who were homozygous for the Ser
680 variant were more
likely to have had a high response than women who were
homozygous for Asn
680 (24% vs. 12%, respectively) (p=0.0131).
These observations were also confirmed in the homogeneous
subgroup (p=0.046) (Figure 1).
The Combination of FSHR and AMH Polymorphisms
(Table 5)
Within both the overall study population and the homogeneous
subgroup, the AMH Ile
49 Ser polymorphism was not associated
with any clinical or hormonal parameters or the number of
oocytes retrieved. However, in both populations, women who
were homozygous for both the FSHR Ser
680 variant and AMH
Ser
49 variant yielded more mature oocytes than women who were
homozygous for FSHR Asn
680 and/or homozygous for AMH Ile
49
with 10.365.5 and 7.363.9 mature oocytes (p=0.0068) in overall
study population and 12.863.7 vs. 7.963.9 mature oocytes
(p=0.009) in the homogenous subgroup.
In the overall study population, we observed that women who
were homozygous for the FSHR Ser
680 and AMH Ser
49 variants
were less likely to have had a low response than women who were
homozygous for FSHR Asn
680 and/or homozygous for AMH Ile
49
(14% vs. 24%, respectively). Similarly, women who were
homozygous for the FSHR Ser
680 and AMH Ser
49 variants were
Table 2. Association of SNPs selected with ovarian response outcome.
Polymorphism p value p value after Holm’s correction
Overall study population Homogeneous population Overall study population Homogeneous population
TNF 0.0955 0.9654 0.8595 1
PAI 0.4745 0.2068 1 1
MTHFR2 0.4177 0.3987 1 1
HLAG 0.1431 0.7065 1 1
BMP15 0.5599 0.0786 1 0.4680
ESR1 0.7381 0.6716 1 1
AMHR 0.4288 0.1247 1 0.4070
MTHFR1 0.1921 0.8440 1 1
AMH 0.1268 0.0747 1 0.6903
VEGF 0.6470 0.5295 1 1
doi:10.1371/journal.pone.0038700.t002
Table 3. Multivariate analysis results in both populations.
Population
Gene
Overall studied
n=427
Homogenous
n=112
ESR2 0.0511 Not included
p53 0.1685 Not included
FSHr680 0.1969 0.0002
Age 0.9017 0.3842
FSH level at J3 0.1409 Not included
doi:10.1371/journal.pone.0038700.t003
Genetic Polymorphisms Impact on Ovarian Response
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38700T
a
b
l
e
4
.
T
h
e
F
S
H
R
(
A
s
n
6
8
0
S
e
r
)
p
o
l
y
m
o
r
p
h
i
s
m
:
b
a
s
e
l
i
n
e
p
o
p
u
l
a
t
i
o
n
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
,
t
r
e
a
t
m
e
n
t
p
a
r
a
m
e
t
e
r
s
a
n
d
o
v
a
r
i
a
n
r
e
s
p
o
n
s
e
.
C
a
n
d
i
d
a
t
e
S
N
P
(
r
s
)
P
o
p
u
l
a
t
i
o
n
G
e
n
o
t
y
p
e
N
u
m
b
e
r
o
f
w
o
m
e
n
A
g
e
(
y
e
a
r
s
)
D
a
y
-
3
F
S
H
l
e
v
e
l
(
I
U
/
l
)
D
a
y
-
3
L
H
l
e
v
e
l
(
I
U
/
l
)
A
m
o
u
n
t
o
f
e
x
o
g
e
n
o
u
s
F
S
H
r
e
q
u
i
r
e
d
f
o
r
o
v
u
l
a
t
i
o
n
i
n
d
u
c
t
i
o
n
(
I
U
)
O
e
s
t
r
a
d
i
o
l
l
e
v
e
l
o
n
t
h
e
d
a
y
o
f
h
C
G
a
d
m
i
n
i
s
t
r
a
t
i
o
n
(
p
g
/
m
l
)
N
u
m
b
e
r
o
f
m
a
t
u
r
e
o
o
c
y
t
e
s
F
S
H
R
(
r
s
6
1
6
6
)
O
v
e
r
a
l
l
s
t
u
d
y
p
o
p
u
l
a
t
i
o
n
A
s
n
/
A
s
n
1
4
2
3
0
.
1
6
1
2
.
6
6
.
6
6
3
.
1
4
.
2
6
2
.
0
2
3
8
4
6
9
4
7
2
1
9
7
6
9
4
1
7
.
1
6
3
.
9
A
s
n
/
S
e
r
1
9
1
3
2
.
0
6
4
.
6
a
1
7
.
7
6
4
.
0
b
1
4
.
8
6
2
.
4
c
1
2
3
8
6
6
9
7
6
2
1
8
4
6
9
0
8
7
.
6
6
3
.
9
S
e
r
/
S
e
r
9
4
3
2
.
0
6
5
.
3
7
.
3
6
2
.
8
4
.
8
6
2
.
2
2
3
8
6
6
8
9
9
2
1
7
2
6
1
0
0
5
8
.
1
6
4
.
3
d
,
e
,
f
A
s
n
/
S
e
r
+
S
e
r
/
S
e
r
2
8
5
3
2
.
0
6
4
.
8
a
$
7
.
6
6
3
.
7
b
$
4
.
8
6
2
.
3
c
$
2
2
0
7
6
9
5
1
2
2
0
7
6
9
5
1
7
.
7
6
4
.
0
H
o
m
o
g
e
n
e
o
u
s
s
u
b
g
r
o
u
p
A
s
n
/
A
s
n
4
5
3
0
.
3
6
3
.
5
6
.
5
6
1
.
7
4
.
0
6
1
.
5
2
3
5
3
6
8
1
9
2
1
2
8
6
8
0
2
7
.
2
6
4
.
0
A
s
n
/
S
e
r
4
6
3
0
.
7
6
3
.
7
6
.
0
6
1
.
7
4
.
5
6
2
.
3
2
2
8
7
6
7
4
8
2
2
4
5
6
8
4
4
8
.
1
6
3
.
3
S
e
r
/
S
e
r
2
1
3
0
.
7
6
3
.
0
6
.
8
6
1
.
5
4
.
2
6
2
.
2
2
2
7
8
6
8
1
5
2
2
7
1
6
9
6
2
9
.
8
6
4
.
6
g
,
h
,
i
A
s
n
/
S
e
r
+
S
e
r
/
S
e
r
6
7
3
0
.
7
6
3
.
5
6
.
3
6
1
.
7
4
.
4
6
2
.
2
2
2
4
8
6
7
6
4
2
2
5
3
6
8
7
5
8
.
6
6
3
.
8
T
h
e
m
a
j
o
r
a
l
l
e
l
e
w
a
s
u
s
e
d
a
s
a
r
e
f
e
r
e
n
c
e
.
a
1
p
v
a
l
u
e
0
.
0
4
1
4
a
$
p
v
a
l
u
e
=
0
.
0
2
4
1
.
b
1
p
v
a
l
u
e
=
0
.
0
0
7
1
,
b
$
p
v
a
l
u
e
=
0
.
0
1
2
6
.
c
1
p
v
a
l
u
e
c
=
0
.
0
3
2
5
,
c
$
p
v
a
l
u
e
=
0
.
0
2
0
7
.
d
,
e
,
f
U
n
i
v
a
r
i
a
t
e
p
v
a
l
u
e
=
0
.
0
0
4
7
,
U
n
i
v
a
r
i
a
t
e
p
a
f
t
e
r
H
o
l
m
’
s
c
o
r
r
e
c
t
i
o
n
=
N
S
,
m
u
l
t
i
v
a
r
i
a
t
e
p
v
a
l
u
e
=
N
S
.
g
,
h
,
I
U
n
i
v
a
r
i
a
t
e
p
v
a
l
u
e
=
0
.
0
0
0
9
,
U
n
i
v
a
r
i
a
t
e
p
a
f
t
e
r
H
o
l
m
’
s
c
o
r
r
e
c
t
i
o
n
=
0
.
0
2
2
5
,
m
u
l
t
i
v
a
r
i
a
t
e
p
v
a
l
u
e
=
0
.
0
0
0
2
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
8
7
0
0
.
t
0
0
4
Genetic Polymorphisms Impact on Ovarian Response
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38700more likely to have a high response than women who were
homozygous for FSHR Asn
680 and/or homozygous for AMH Ile
49
(43% vs. 14%, respectively) (p=0.0188). These observations were
confirmed in the homogeneous subgroup (p=0.004) (Figure 2).
The Oestradiol Receptor 2 Polymorphism
(ESR2+1730 G.A) (Table 6)
In the overall study population, there was no association
between this polymorphism and the day-3 serum levels of LH and
FSH. However, in the homogeneous subgroup, an elevated LH
serum level was observed for heterozygous women, with mean LH
levels of 3.761.4, 4.862.3 and 3.761.6 IU/l for the GG, GA and
AA genotypes, respectively. Day-3 E2 and FSH levels did not vary
with genotype in the homogeneous subgroup.
The amount of FSH administered was not associated with the
polymorphism in the overall study population. However, the mean
E2 level on the day of hCG administration was higher in women
who were homozygous for the G allele (239661015 pg/ml) than
in heterozygous women and women who were homozygous for the
A allele (20676726, p=0.0016 and 20496915 pg/ml, p=0.0155
respectively).
In the overall study population, women who were homozygous
for the G allele had a greater mean number of mature oocytes
than (i) women who were heterozygous for the A allele (8.164.2
vs. 7.264.0, respectively; p=0.0017) or (ii) group of women who
were homozygous or heterozygous for the A allele (8.164.2 vs.
7.263.9, respectively; p =0.0314).
The results differed in the homogeneous subgroup, where the
number of mature oocytes was not associated with the polymor-
phism. However, women who were homozygous for the A allele
required more exogenous FSH (27066879 IU) than women who
were homozygous or heterozygous for the G allele (23756752 IU
and 21456744 IU respectively) to produce a similar number of
oocytes.
In the overall study population, the ESR2 polymorphism was
still significantly correlated with the oocyte number after applying
Holm’s correction (p=0.0425) but not after a multivariate analysis
(p=0.0511). In both populations, there were no relationships
between this polymorphism and the likelihood of a low or high
response.
The p53 Gene Polymorphism (p.Arg
72Pro, +215 C.G)
(Table 7)
In both populations, there were no genotype-related differences
in terms of age, day-3 hormone levels, the amount of FSH
required for ovulation induction and the E2 level on the day of
HCG administration.
In the overall study population, the number of mature oocytes
obtained was not significantly associated with the genotype).
In the homogeneous subgroup, women who were homozygous
for the Arg
72 variant had a greater number of oocytes than (i)
women who were heterozygous for the Pro
72 variant (8.863.9 vs.
7.063.3, respectively; p=0.0048) and (ii) group of women who
were homozygous and heterozygous for Pro
72 variant (8.863.9 vs.
7.263.3, respectively; p =0.0451). However, this difference was
no longer significant after applying Holm’s correction and a
multivariate analysis.
Figure 1. Poor and high response risks, according to FSHR
680 polymorphism genotypes.
doi:10.1371/journal.pone.0038700.g001
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women who were homozygous for Arg
72 were less likely to have a
low response than women who were heterozygous or homozygous
for the Pro
72 allele (15% vs. 28%, respectively). Accordingly, the
women who were homozygous for Arg
72 were more likely to show
a high response than those who were heterozygous or homozygous
for Pro
72 allele (23% vs. 12%, respectively; p=0.0429) (Figure 3).
Discussion
Of the thirteen polymorphisms studied here, only three SNPs (in
the genes coding for FSHR, ESR2 and p53) and one SNP
combination (FSHR Asn
680Ser/AMH Ile
49Ser) appeared to be
significantly associated with the number of mature oocytes
retrieved after COH. To improve our analysis, we applied Holm’s
correction for p-values and performed a multivariate analysis to
evaluate the polymorphisms’ respective impacts on the women’s
IVF results.
The polymorphisms studied here have been previously shown to
affect the response in some but not all studies.
We did not genotype FSHr307 in the current study because it is
in near-complete linkage disequilibrium with FSHr680 [16]. In the
present study, we investigated gene-environment interactions.
Both genetic variants and environmental factors (as age, ovulation
and length of cycle) have a significant influence on the ovarian
response to gonadotrophins.
We showed that some effects are not apparent in the unselected
ICSI population and clearly highlights the care that must be taken
when comparing these studies. For example, FSH and LH levels
on day 3 were not dependant on the FSH receptor polymorphism
but a difference was found in the total unselected ICSI population.
Thus, differences between studies might reflect the heterogeneity
of included patients. In the homogeneous subgroup, the woman’s
age and FSH level had less impact on the number of oocytes
retrieved and so clearer conclusion could be drawn in this respect -
even though the sample size was very small.
The FSH Receptor Polymorphism (FSHR p.Asn
680Ser,
FSHR 2039 A.G)
In the homogeneous subgroup, there was no relationship
between the genotype on one hand and the day-3 FSH level or
age on the other - mainly because an FSH level below to 10 IU/l
and age under 38 were criteria for inclusion in this subgroup.
In contrast, in the overall study population, we found that a
significantly higher day-3 serum FSH level was associated with the
FSHR Ser
680 variant. The increased age might explain the
increased day 3 FSH. These data indicate that the polymorphism
has no effect on young patients but might interfere when the
patients are getting older.
The genotype did not appear to be associated with the amount
of exogenous FSH. The attending gynaecologists were blinded to
the genotype at the time of prescription. Similarly, there was no
FSHR genotype-related difference in the E2 level on the day of
hCG administration.
As described in the Results section, the women who were
homozygous for the FSHR Ser
680 variant were less likely to have
been low responders and more likely to have been high
responders. These results were confirmed in the overall study
population. Furthermore, the statistical significance after Holm’s
correction and a multivariate analysis confirmed the impact of the
FSHr680 genotype on the ovarian response to rFSH in IVF cycles.
Several previous studies have sought a correlation between the
FSHR polymorphism and the outcome of the ovarian response
but yielded discordant results.
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38700In contrast with our present results, it has been reported that
FSHR Asn
680Ser is associated with a low E2 level during ovarian
stimulation. To achieve similar oestradiol peak levels, homozygous
FSHR Ser
680 women were found to need more exogenous FSH
than women with FSHR Asn
680 [11,12,17]. Indeed, other
researchers have suggested that women with the FSHR Ser
680
polymorphism have a higher ovarian threshold for FSH and thus a
longer follicular cycle. The FSHR Ser
680 polymorphism has also
been linked to lower sensitivity to the action of FSH [18].
Other studies have not found any association between FSHR
Ser
680 polymorphism and various baseline hormone levels or the
amount of exogenous FSH required for ovarian stimulation [19–
22]. More recently, it was reported that women who were
homozygous for the FSHR Asn
680 polymorphism needed higher
amounts of exogenous FSH and tended to need more stimulation
days [23]. This observation is concordant with our present study,
in which women who were homozygous for FSHR Asn
680 had
fewer mature oocytes than women homozygous for FSHR Ser
680
(despite the administration of similar amounts of exogenous
FSH).
In other studies, women who were homozygous for the FSHR
Ser
680 polymorphism were more at risk of a high response and
iatrogenic OHSS after similar ovarian stimulation [22,24]. Only
the occurrence of moderately intense OHSS was correlated with
the FSHR Ser
680 polymorphism [24]. Our results were similar,
with an increased likelihood of a high response ($12 mature
oocytes) for women who were homozygous for the FSHR Ser
680
polymorphism. The occurrence of iatrogenic hyperstimulation is
probably linked to the hypersensitivity to FSH; this is quite
unexpected because the Ser
680 polymorphism has previously been
correlated with low sensitivity to FSH [11].
There is currently no evidence of an effect of the FSHR
genotype on hormone binding characteristics or cAMP or inositol
phosphate production following FSH stimulation. It is also possible
that the FSHR Asn
680Ser polymorphism only has a direct impact
on the ovarian gonadotrophin response and oocyte recruitment
when it is combined with other polymorphisms.
This hypothesis was strengthened by the results of our study,
since the association between the FSHR polymorphism and the
number of mature oocytes appeared to be higher when combined
Figure 2. Poor and high response risks, according to FSHR
680 and AMH
49 polymorphism genotypes.
doi:10.1371/journal.pone.0038700.g002
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49Ser polymorphism (which is thought to slightly
alter the biological activity of AMH [25]).
In both the overall study population and the homogeneous
subgroup, the AMH Ile
49Ser polymorphism alone was not
significantly associated with baseline day-3 hormone levels or the
number of mature oocytes recovered after COH. Our results agree
with previous data in this respect (Hanevik et al. 2010).
In both the overall study population and the homogeneous
subgroup, we found that women who were homozygous for both
the FSHR Ser
680 and the AMH Ser
49 alleles had a significantly
greater mean number of mature oocyte numbers than women
who were homozygous for FSHR Asn
680 and/or homozygous for
AMH Ile
49– even though the various groups received similar
amounts of exogenous FSH. A genotype-related difference was
also present in the overall study population and the homoge-
neous subgroup when we compared the likelihood of belonging
to the subgroups formed according to the number of oocytes. An
increased likelihood of a high response was observed for women
who were homozygous for both the FSHR Ser
680 and the AMH
Ser
49 alleles, when compared with women who were homozy-
gous for FSHR Asn
680 and/or homozygous for AMH Ile
49.
It has been shown that AMH-knockout mice display fast, high-
quality primordial follicle recruitment and have a more
pronounced response than the wild type in the presence of high
serum FSH concentrations. In view of these data, AMH inhibits
primordial follicle growth in vitro [26–28] and attenuates
sensitivity to FSH. Conversely, follicles are more responsive to
FSH in the absence of AMH [29,30].
These data are in agreement with our results, which suggest that
AMH and FSH polymorphisms might improve the recruitment of
primordial follicles. Our findings also suggest that the combination
of AMH and FSHR polymorphisms may have potential value as a
Figure 3. Poor and high response risks, according to p53
72 polymorphism genotypes.
doi:10.1371/journal.pone.0038700.g003
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38700marker for the ovarian response in women undergoing IVF
treatment but due to sample size this finding needs to be
confirmed.
The Oestrogen Receptor b Gene Polymorphism
(ESR2+1730 G.A)
In the overall study population, women who were heterozygous
or homozygous for the A allele had a significantly greater number
of mature oocytes than those who were homozygous for the G
allele, despite receiving similar amounts of exogenous FSH.
Statistical impact of ESR2+1730 genotype on ovarian response to
rFSH in IVF cycle was confirmed using Holm’s correction but not
using multivariate analysis. This discrepancy is probably due to
sample size, limited for multivariate analysis.
No difference was observed in the homogeneous subgroup;
women who were homozygous for the A allele needed to receive
more exogenous FSH than women who were heterozygous for the
A allele (27066879 IU and 21456744 IU, respectively;
p=0.0150) to achieve adequate oocyte maturation and obtain a
similar number of oocytes. Heterozygous women received similar
amounts of exogenous FSH when compared with women who
were homozygous for the G allele but had a higher day-3 LH
level; which may contribute to best final adequate oocytes
maturation. There were no genotype-related differences in the
likelihood of belonging to the low-response or high-response
groups.
In view of previous reports [31] associating ESR2 polymor-
phism with ovulatory dysfunction, we believe that our fertility-
based inclusion criteria for the homogeneous subgroup (i.e.
excluding women with known causes of infertility) can explain
why the ESR2 polymorphism was not associated with the nature
of the ovarian response.
Although oestrogen’s action is mediated by the ESR1 and ESR2
receptors, the latter predominates in the ovary [32,33]. ESR2
stimulates early folliculogenesis, decreases follicular atresia and
stimulates late follicular growth [34] by inducing the action of
FSH. In turn, FSH promotes granulosa cell proliferation. ESR2
action may thus explain the synergistic effect of oestrogen and
FSH on the number of FSH receptors in granulosa cells (resulting
in follicular growth and maturation [35]). However, our data did
not reveal an association between the FSHR p.Asn
680Ser and
ESR2+1730 G.A polymorphisms on ovarian response.
ESR2 knockout mice have inefficient ovulation efficiency and
produce few oocytes. This is mainly due to a defect within ovarian
tissue in general [36], [37] and inability of E2 to exert its effect on
the granulosa cells in maturing follicles in particular. Furthermore,
it has been shown that ESR2 had no effect on the serum
concentration of pituitary reproductive hormones [38]. Our results
are in agreement with ESR2-knockout mouse data, since the
mRNA of the ESR2+1730 A variant folds differently and is
expressed less [39]. Furthermore, it has also been shown that
follicles with low oestrogen level had low-quality, apoptotic oocytes
[40,41], which could reduce the number of mature oocytes.
Hence, our results suggest that the ESR2+1730 G.A poly-
morphism modulates the IVF outcome by affecting the number of
mature oocytes.
The p53 Gene Polymorphism (p. Arg
72Pro, +215 G.C)
In the overall study population and in the homogeneous
subgroup, the FSH treatment did not vary as a function of the p53
polymorphism. However, for the homogeneous subgroup, we
observed that women who were homozygous for the Arg
72 allele
had a significantly higher mean number of retrieved oocytes than
women who were heterozygous or homozygous for the Pro
72
polymorphism. As this result was no longer statistically significant
after Holm’s correction and a multivariate analysis, these data
should be considered with a degree of caution. Further analyses
are required to confirm or repudiate this finding.
Moreover, the genotype p53 Arg
72 appeared to increase the
likelihood of a high response and decrease the likelihood of a low
response in the homogeneous subgroup.
The p53 tumour suppressor protein plays a crucial role in
maintaining genomic stability in somatic cells. It has been shown
that small changes in the level and/or activity of p53 can alter its
functional efficiency. In Drosophila and C. elegans, p53 protein is
most commonly expressed in germ cells, where it eliminates
defective gametes and, consequently, defective offspring from the
population [42,43].
The first report of an impact of p53 on fertility found a high
association between the Pro
72 polymorphism and recurrent
implantation failure [44]. It has been further suggested that p53
Table 8. Women characteristics.
Women characteristics Overall study population Homogeneous subgroup
Patients number (n=) 427 112
Age (years) 31,269.55 30.663.53
Hormonal profile Day-3 E2 level(IU/ml) 46.27626.15 46.89628.17
Day-3 LH level (IU/ml) 4.6462.77 4.3262.02
Day-3 FSH level (IU/ml) 7.0262.44 6.4061.74
ICSI indication IVF failure 28.6% 0%
Male infertility 71.4% 100%
Menstruel cycle Normal 77.6% 100%
Abnormal 22.4% 0%
Ovulation Normal 21.7% 100%
Abnormal 78.3% 0%
Ethnic origin Caucasian 80% 100%
Others 20% 0%
doi:10.1371/journal.pone.0038700.t008
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PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e38700regulates female reproduction and blastocyst implantation through
transcriptional up-regulation of uterine leukocyte inhibitory factor
(LIF), which is an important factor in implantation. Elevated
endometrial LIF levels are observed at the time of implantation in
fertile women [45]. Women with unexplained infertility have
lower LIF levels than fertile women do [46,47].
In agreement with our present results, it has been reported that
the Pro
72 polymorphism is highly associated with decreased
pregnancy rates after fresh IVF, via an ovarian mechanism [48].
Even though functional impact of p53 on oogenesis has not yet
been investigated, one can hypothesize that low p53 activity is
associated with greater DNA damage during folliculogenesis and
oogenesis. Although genetic predispositions must always be
confirmed in larger series, the p53 Arg
72Pro polymorphism
appears to have a significant impact on the ovarian response in
women undergoing IVF treatment.
In conclusion, our objective was to determine a genetic profile
suitable for use prior to the IVF protocol, in order to adjust the
amount of prescribed FSH. We genotyped women after
participation in an IVF protocol and investigated the potential
usefulness of genetic testing for predicting the COH response.
On the basis of literature reports, we identified thirteen
polymorphisms that may impact ovarian function. Using a
univariate statistical analysis, we found that three of the latter
polymorphisms (in the genes coding for the FSHR, ESR2 and
p53) and one combination of polymorphisms (FSHr680/AMH)
were significantly associated with the number of mature oocytes
retrieved after COH. After Holm’s correction and a multivariate
analysis, p53 was no longer statistically significant.
There is a need for clinical studies in which the amount of FSH
given to patients is modulated according to the genotype -
especially for women who are genetically predisposed to low or
high responses to COH.
Materials and Methods
Subject Population
The study was approved by an independent ethics committee
(the Comite ´ Consultatif de Protection des Personnes dans la Recherche
Biome ´dicale; project reference: 01032) and was performed in
accordance with the tenets of the Declaration of Helsinki. All
the women provided their prior, written, informed consent to
participation.
We included a total of 427 women undergoing an initial ICSI
procedure with oocyte retrieval and embryo transfer for severe
male infertility. Before the ICSI procedure, the patients had been
extensive evaluated in terms of their personal and family medical
history, clinical and serological status, hysterosalpingography,
day-three hormonal profile (FSH, luteinizing hormone and
estrogen) and karyotype. The exclusion criteria included, prior
chemotherapy, unilateral ovariectomy, maternal diethylstilbene
treatment, an abnormal karyotype or any identified genetic
abnormalities.
To lessen the impact of age and FSH level on our results, we
then selected a Caucasian subgroup (n=112) that was homoge-
neous in terms of age and the absence of known aetiological factors
for female infertility. The criteria for this subgroup were as follows:
Caucasian origin, normal karyotype, age under 38, a day-three
serum FSH level below 10 IU/l and the combination of a long
Table 10. Primer design for the selected SNPs.
Gene name
Reference
sequence Primer (59-39)
PCR product
size
AMH rs10407022 F1 F2 R CACAGAGGCTCTTGTGGGC CACAGAGGCTCTTGTGGGA
GATAGGGGTCTGTCCTGCAC
FAM HEX 247
AMHR rs2002555 F1 F2 R CCTTCCTCTGCCCAAGCA CCTTCCTCTGCCCAAGCG
CCAGCTGAGAACCCAGTGAT
FAM HEX 207
BMP15 rs3810682 F1 F2 R GAGGAGGACCATCTTGAAAGG GAGGAGGACCATCTTGAAAGC
ATGAGGCAACTTTGGTCCAG
FAM HEX 197
ESR1 rs2234693 F1 F2 R GAGTTCCAAATGTCCCAGCT GAGTTCCAAATGTCCCAGCC
GGGGAAATTGTTTATTGCAAAC
FAM HEX 234
ESR2 rs4986938 F1 F2 R GGCCCACAGAGGTCACAG GGCCCACAGAGGTCACAA
CTTCCTCACACCGACTCCTG
FAM HEX 157
FSHR rs6166 F1 F2 R GACAAGTATGTAAGTGGAACCAT
GACAAGTATGTAAGTGGAACCAC TGTTTCACCCCATCAACTC
HEX FAM 224
HLA-G F1 F2 R TGAAACTTAAGAGCTTTGTGAGTCC
TGAAACTTAAGAGCTTTGTGAGTCG AGTTGTGCCTGAGTGCATGA
FAM HEX 191
MTHFR1 rs1801133 F1 F2 R GAAGGTGTCTGCGGGAGC GAAGGTGTCTGCGGGAGT
AGAACTCAGCGAACTCAGCA
FAM HEX 238
MTHFR2 rs1801131 F1 F2 R GAGGAGCTGACCAGTGAAGC GAGGAGCTGACCAGTGAAGA
ACAGGATGGGGAAGTCACAG
HEX FAM 178
p53 rs10425222 F1 F2 R CAGAGGCTGCTCCCC CAGAGGCTGCTCCCG
GACTTGGCTGTCCCAGAATG
FAM HEX 163
PAI rs1799889 F1 F2 R TCAGGGGCACAGAGAGAGTC TCAGGGGGCACAGAGAGAGTC
CAGCCACGTGATTGTCTAGG
FAM HEX 148
149
TNF rs1800629 F1 F2 R ATAGGTTTTGAGGGGCATGA ATAGGTTTTGAGGGGCATGG
GAGTCTCCGGGTCAGAATGA
FAM HEX 184
VEGF rs2010963 F1 F2 R CTCACTTTGCCCCTGTCG CTCACTTTGCCCCTGTCC
GAGGCGCAGCGGTTAG
HEX FAM 351
doi:10.1371/journal.pone.0038700.t010
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PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e38700GnRH agonist desensitization protocol and treatment with
recombinant FSH for COH. The exclusion criteria included
uterine malformation, grade 3 or 4 endometriosis, polycystic ovary
syndrome (PCOS). Clinical and demographic characteristics were
described in Table 8.
Ovarian follicle stimulation was performed with recombinant
FSH (GonalFH from Merck Serono or PuregonH from Organon-
Schering Plough) and monitored by estrogen measurements and
transvaginal ultrasound from day 5 onwards. Ovulation was
induced with 10,000 IU of hCG or recombinant hCG. Transvag-
inal, ultrasound-guided follicle aspiration was performed 35 hours
later and maturity of oocytes with a single polar body was
evaluated after hyaluronidase treatment.
The number of mature oocytes obtained after ovarian
hyperstimulation was analysed by genotype. In order to evaluate
the association between the SNPs and the average number of
oocytes in response to COH, we divided the population into three
categories: low responders (4 oocytes or less), normal responders
(between 5 and 11 oocytes) and high responders (12 oocytes or
more).
DNA Preparation
For each patient, a blood sample was collected for DNA
analysis. Genomic DNA was extracted using the WizardH
Genomic DNA Purification Kit (Promega, Southampton, UK),
according to the manufacturer’s protocol. Genotyping was
performed after the IVF procedures had been completed.
SNPs Selected for Genotyping
We selected thirteen SNPs that reportedly impact the ovarian
response and/or embryo implantation in women in IVF
programmes (Table 9):
Primer Design
For each of these thirteen selected SNPs, an allele-specific PCR
assay was developed. Primer pairs were designed using Primer3
online software (www.ncbi.nlm) (Table 10). Each primer set was
carefully designed for compatibility with a multiplex PCR assay,
with a (i) products between 150–350 base pairs that can be
identified on capillary electrophoresis and (ii) a melting temper-
ature (Tm) close to 6062uC. Each allele-specific forward or reverse
primer was marked with either 6-carboxyfluorescein (FAM, blue
colour) or hexachlorocarboxyfluorescein (HEX, green colour) and
synthesized by Eurogentec (Serain, Liege, Belgium). After receipt,
primers were diluted to an appropriate concentration for PCR
assays in 10 mM Tris buffer and stored at 220uC until use.
Allele-specific PCR Validation
The 20 ml PCR reaction mixture (QIAGEN Hilden, Germany)
contained 2 ml of extracted DNA, 0.2 mM of each primer. A Silver
96-Well GeneAmp 2700 PCR System was used for DNA
amplification. A denaturation step was first performed (15 min
at 95uC) followed by 24 PCR cycles (denaturation: 30 seconds at
94uC; annealing: 90 seconds at 65uC; extension: 60 seconds at
72uC) and a final extension phase (30 min at 60uC). All
experiments were repeated twice.
Multiplex PCR Conditions
Multiplex PCR was carried out in 20 ml reaction volumes,
containing 2 ml of extracted DNA containing 0.2 mM of all
primers Thermal cycling was performed using the conditions
described above. All experiments were also repeated twice.
Genotyping
PCR products were diluted 1:10 in sterile water, and 1 mLo f
this dilution was added to 20 mL of a mixture containing 19.5 mL
FormamideH (Applied Biosystems, Foster City, California, USA)
Figure 4. Electrophoregram profile with the 13 polymorphisms genotyped. The first and second lines show alleles fluorescently tagged
with FAM and Hex dyes, respectively. The last electropherogram is the RO6500 size standard.
doi:10.1371/journal.pone.0038700.g004
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PCR plates. The samples were denatured for 3 min at 95uC.
Multiplex PCR products were separated by capillary electro-
phoresis using an ABI Prism 3100 genetic analyzer (Applied
Biosystems). Allelic call was performed using the GenemapperH ID
v.3.1 software (Applied Biosystem) (Figure 4).
Statistics
Statistical analysis was performed in three steps:
1. Univariate analysis. For age, the day-3 serum levels of
LH and FSH, the amounts of exogenous FSH and the oestradiol
level on the day of hCG administration, means were compared in
an analysis of variance. The threshold for statistical significance
was set to 5%.
For the oocyte number, the means were compared using
generalized linear models (GLMs) supported by the GENMOD
procedure (SAS Institute Inc., Cary, NC, USA), with the
hypothesis of a Poisson distribution for the response variable.
For each genotype, the respective proportions with a high
response ($12 mature oocytes) and a low response (#4 mature
oocytes) were compared in a Stat view program (SAS institute)
using Chi-2 and Fisher tests.
To take into account multiple testing for the polymorphisms, the
familywise error rate was adjusted with the sequential Bonferroni-
Holm procedure [49]. Deviations from the Hardy-Weinberg
equilibrium were assessed by means of a Chi-2 test.
2. Multivariate analysis. We performed a multivariate
analysis with all polymorphisms and putative confounding clinical
factors (age, FSH level, cycle length and ease of ovulation). All
polymorphisms found to be significant at p#0.30 after Holm’s
correction were introduced as covariates into GLM models. Any
suitable, first-order interactions derived from these factors were
also added as covariates. Final models were obtained using
backward selection of variables, with the likelihood ratio as the
selection criterion. Variables with p.0.05 and ,0.10 were kept in
the final models.
3. Multilocus analysis. Lastly, in order to better identify
polymorphism interactions, a multilocus analysis was performed
with GLM models. All polymorphisms found to be significant at
p#0.075 in the univariate analysis (without Holm correction) were
introduced into the multilocus analysis; this enabled us to decrease
the number of independent covariates in the models. Backward
selection of variables was performed as above, and variables with
p.0.05 and ,0.10 were kept in the final models.
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